MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria and Protein Potential Host Shari Davis Who Facilitated a Discussion: Let’s Talk About Race & Racism
In an effort to support the end of, and continue the discussion about systemic racism, Sanaria Inc. and Protein Potential, LLC hosted Ms. Shari Davis, ACC, SPHR, SHRM-SCP, President and CEO of Venture HCM LLC. Ms. Davis gave a presentation to and facilitated a discussion with our staff about the Black Lives Matter movement.
Sanaria’s CEO Interviewed About Development of a COVID-19 Vaccine
More than 130 labs around the world are working to develop a COVID-19 vaccine. But what would it take to vaccinate everyone by early next year?
Sanaria Recognized for Global Health Partnership in the Fight Against Malaria in BioBuzz
The ultimate goal for Sanaria is eradication of malaria from the planet. What started as a shot in the dark, cold call from Sanaria, has evolved into truly remarkable global health collaboration with Marathon Oil, Noble Energy, AMPCO, and the Government of Equatorial Guinea, that has the potential to fundamentally change the world for the better.
Sanaria and Protein Potential Recognized for Efforts Against COVID-19 in BioBuzz
Sanaria and Protein Potential, which are co-located in Rockville, Maryland, are working on a number of initiatives to combat COVID-19. Dr. Stephen L. Hoffman is the CEO and Chief Scientific Officer at Sanaria, which is a leading global malaria vaccine biotechnology company. Dr. Kim Lee Sim is the President and Chief Scientific Officer at Protein Potential, an R&D group focused on vaccine development and innovative DNA and protein products. She is also the Executive Vice President of Process Development and Manufacturing at Sanaria.
i-PfSPZ-C Meets in Rockville, MD on November 18th and 19th, 2019
On 18 and 19 November 2019, Sanaria hosted the semi-annual International PfSPZ Consortium (i-PfSPZ-C) meeting at the University of Maryland Institute for Bioscience and Biotechnology Research in Rockville, MD.
Sanaria Attended the 68th ASTMH Meeting
From 20-24 November 2010, Sanaria participated in the 68th Annual ASTMH (American Society of Tropical Medicine and Hygiene) Meeting held at the Gaylord Resort in Washington, D.C.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.